This condition is characterized by high blood sugar levels, the presence of ketones in the blood, and metabolic acidosis. DKA can be life-threatening and is often the first sign of type 1 diabetes ...
In March 2019, the FDA opted not to approve sotagliflozin when it issued a complete response letter. Concerns over DKA were again brought up again when the FDA Endocrinologic and Metabolic Drugs ...
We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA ... or malaise or develop a metabolic acidosis in the setting of SGLT-2 inhibitor therapy should be promptly ...